Value Bridge — GEISINGER WYOMING VALLEY MED CTR
Current $47M → Target $64M (+$17.3M)
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
$46.6M
Current EBITDA
$63.9M
Target EBITDA
+$17.3M
Total Uplift
7
Value Levers
EBITDA Bridge — 7 Lever Model
Each lever shows gross impact, probability of achievement, and probability-weighted value.
Denial Rate Reduction
$0.0M
AR Acceleration
$0.0M
Coding Accuracy Uplift
$3.9M
Payer Mix Optimization
$9.4M
Cost to Collect Reduction
$3.1M
Clean Claim Improvement
$2.3M
Volume & Rate Growth
$15.7M
What This Means
The 7-lever model projects a 37% EBITDA uplift from $47M to $64M. The highest-impact lever is Volume & Rate Growth at $6.3M probability-weighted.
IC talking point: "We see $17M in annual EBITDA improvement, primarily from volume & rate growth. At an 11x multiple, this represents $190M in equity value creation."